Our conclusions and observations extend beyond severe asthma, presenting CHIT1 inhibition as a novel and attractive therapeutic target for other disorders regulated by profibrotic macrophages, specifically IPF and other ILDs. Here, CHIT1 is linked to idiopathic pulmonary fibrosis.